The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized Phase 2a study to assess pharmacodynamics, antitumor activity and safety of intravenous BAL101553, a novel microtubule inhibitor, at two dose levels in adult patients with selected advanced solid tumors.
 
Rebecca Sophie Kristeleit
Honoraria - Clovis Oncology; Novartis; Roche/Genentech
Consulting or Advisory Role - Clovis Oncology; Novartis
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; PiQuR
 
Alan D. Smith
No Relationships to Disclose
 
Noor R Md Haris
No Relationships to Disclose
 
Ishtiaq Husain Zubairi
No Relationships to Disclose
 
Judy W. King
No Relationships to Disclose
 
Maria Jose de Miguel Luken
No Relationships to Disclose
 
Manolo D'Arcangelo
No Relationships to Disclose
 
Julie MacDonald
No Relationships to Disclose
 
Nicholas F. Brown
No Relationships to Disclose
 
Alan Hilary Calvert
Travel, Accommodations, Expenses - Basilea
 
Alison L. Hannah
Consulting or Advisory Role - Basilea
 
Stephanie Anderson
Employment - Basilea
Stock and Other Ownership Interests - Basilea
 
Felix Bachmann
Employment - Basilea
Stock and Other Ownership Interests - Basilea
 
Martina Maurer
Employment - Basilea
Stock and Other Ownership Interests - Basilea
 
Anne Schmitt-Hoffmann
Employment - Basilea
Stock and Other Ownership Interests - Basilea
 
Heidi A Lane
Employment - Basilea
Leadership - Basilea
Stock and Other Ownership Interests - Basilea
Research Funding - Basilea
Patents, Royalties, Other Intellectual Property - Basilea (Inst)
 
Marc Frederick Engelhardt
Employment - Basilea
Stock and Other Ownership Interests - Basilea
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Roche Pharma AG
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Clovis Oncology; Eisai; Genentech; GlaxoSmithKline; Jennerex; Karus Therapeutics; Roche Pharma AG; Transgene
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Roche Pharma AG
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); E-Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Merck (Inst); Otsuka (Inst); PharmaMar (Inst); Roche Pharma AG (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Roche Pharma AG
 
Ruth Plummer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Biomarin; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Roche/Genentech; Tesaro; Vertex
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); e-Therapeutics (Inst); Eisai (Inst); Ipsen (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech
 
L Rhoda Molife
Research Funding - Basilea